MTAP and urothelial carcinoma: Most recently a partial response was reported in 3 and a complete response in one out of 10 MTAP deficient urothelial carcinomas that were previously treated by multiple lines of chemotherapy after single agent treatment by the MAT2A inhibitor IDE39712.